Subscribe to RSS
Download PDF
DOI: 10.1055/s-0044-1782159
The Research Progress of the Application of Bioinformatics in the Diagnosis and Treatment of Alzheimer's Disease
Authors
Funding This work was supported by the National Natural Science Foundation of China (82305087, 82274612), General Project of China Postdoctoral Science Foundation (2022M711080), and Key Research and Development Program of Henan Province (231111312900).
Abstract
Alzheimer's disease (AD) is characterized by a complex pathogenesis, limited diagnostic methods, and a lack of effective therapeutic drugs in clinical settings, posing significant challenges in modern medical research. Bioinformatics offers new perspectives for identifying key pathological biomarkers of AD, analyzing differentially expressed genes in AD, screening for effective drug targets against AD, studying the mechanisms of AD pathogenesis, and discovering novel anti-AD drugs. However, data preprocessing and statistical analysis methods in bioinformatics research can significantly impact results, and there is a lack of consistency and coordination in analysis methods across platforms and laboratories in practical studies, making it difficult to compare data between studies. Therefore, it is crucial to establish standardized operating procedures and quality control protocols, improve the reproducibility of methods across platforms, and promote data comparison between studies.
Keywords
Alzheimer's disease - bioinformatics - Chinese herbs - Chinese herbal compound - biomarkers - therapeutic targetsCRediT Authorship Contribution Statement
Zhiyang Yu: Conceptualization, data curation, software, and writing original draft. Wenpan Wang: Visualization, and formal analysis. Qiong Qiao: Data curation, and writing-review and editing. Yiran Sun: Software and methodology. Zhishen Xie and Junying Song: Project administration, writing-review and editing. Zhenqiang Zhang and Huifen Ma: Funding acquisition, supervision, writing-review and editing.
Publication History
Received: 12 November 2023
Accepted: 29 December 2023
Article published online:
30 March 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Drew L. An age-old story of dementia. Nature 2018; 559 (7715) S2-S3
- 2 GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022; 7 (02) e105-e125
- 3 Roos DS. Computational biology. Bioinformatics—trying to swim in a sea of data. Science 2001; 291 (5507) 1260-1261
- 4 Avram S, Mernea M, Limban C, Borcan F, Chifiriuc C. Potential therapeutic approaches to Alzheimer's disease by bioinformatics, cheminformatics and predicted ADME-Tox Tools. Curr Neuropharmacol 2020; 18 (08) 696-719
- 5 Ren RJ, Yin P, Wang ZH. et al. Report on Alzheimer's disease in China. J Diagn Theory Pract 2021; 20 (04) 317-337
- 6 Jack Jr CR, Bennett DA, Blennow K. et al. Contributors. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018; 14 (04) 535-562
- 7 Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S. Alzheimer's disease CSF biomarkers: clinical indications and rational use. Acta Neurol Belg 2017; 117 (03) 591-602
- 8 Bălașa AF, Chircov C, Grumezescu AM. Body fluid biomarkers for Alzheimer's disease-an up-to-date overview. Biomedicines 2020; 8 (10) 421
- 9 Bader JM, Geyer PE, Müller JB. et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Mol Syst Biol 2020; 16 (06) e9356
- 10 Li Y, Chen Z, Wang Q. et al. Identification of hub proteins in cerebrospinal fluid as potential biomarkers of Alzheimer's disease by integrated bioinformatics. J Neurol 2023; 270 (03) 1487-1500
- 11 Yao F, Zhang K, Zhang Y. et al. Identification of blood biomarkers for Alzheimer's disease through computational prediction and experimental validation. Front Neurol 2019; 9: 1158
- 12 Saha P, Sarkar S, Paidi RK, Biswas SC. TIMP-1: a key cytokine released from activated astrocytes protects neurons and ameliorates cognitive behaviours in a rodent model of Alzheimer's disease. Brain Behav Immun 2020; 87: 804-819
- 13 Tsuneura Y, Nakai T, Mizoguchi H, Yamada K. New strategies for the treatment of neuropsychiatric disorders based on reelin dysfunction. Int J Mol Sci 2022; 23 (03) 1829
- 14 Guo H, Li B, Yao H. et al. Profiling the oral microbiomes in patients with Alzheimer's disease. Oral Dis 2023; 29 (03) 1341-1355
- 15 Rogers BB, Anderson AG, Lauzon SN. et al. Neuronal MAPT expression is mediated by long-range interactions with cis-regulatory elements. Am J Hum Genet 2024; 111 (02) 259-279
- 16 Lunnon K, Ibrahim Z, Proitsi P. et al. AddNeuroMed Consortium. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis 2012; 30 (03) 685-710
- 17 Naughton BJ, Duncan FJ, Murrey DA. et al. Blood genome-wide transcriptional profiles reflect broad molecular impairments and strong blood-brain links in Alzheimer's disease. J Alzheimers Dis 2015; 43 (01) 93-108
- 18 Park YH, Hodges A, Risacher SL. et al. AddNeuroMed consortium and the Alzheimer's Disease Neuroimaging Initiative. Dysregulated Fc gamma receptor-mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis. Neurobiol Aging 2020; 88: 24-32
- 19 Phitthayaphong P, Kumfu S, Chattipakorn N, Chattipakorn SC. Blockage of fc gamma receptors alleviates neuronal and microglial toxicity induced by palmitic acid. J Alzheimers Dis 2021; 82 (03) 1315-1332
- 20 Olah M, Menon V, Habib N. et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer's disease. Nat Commun 2020; 11 (01) 6129
- 21 Mathys H, Davila-Velderrain J, Peng Z. et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature 2019; 570 (7761) 332-337
- 22 Lau SF, Cao H, Fu AKY, Ip NY. Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer's disease. Proc Natl Acad Sci U S A 2020; 117 (41) 25800-25809
- 23 Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet 2013; 52 (04) 225-241
- 24 Tan CC, Yu JT, Wang HF. et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis 2014; 41 (02) 615-631
- 25 Rubin R. Recently approved Alzheimer drug raises questions that might never be answered. JAMA 2021; 326 (06) 469-472
- 26 Sun Y, Zhu R, Ye H. et al. Towards a bioinformatics analysis of anti-Alzheimer's herbal medicines from a target network perspective. Brief Bioinform 2013; 14 (03) 327-343
- 27 Chen YY, Liu QP, An P. et al. Ginsenoside Rd: a promising natural neuroprotective agent. Phytomedicine 2022; 95: 153883
- 28 Wang F, Chen H, Hu Y, Chen L, Liu Y. Integrated comparative metabolomics and network pharmacology approach to uncover the key active ingredients of Polygonati rhizoma and their therapeutic potential for the treatment of Alzheimer's disease. Front Pharmacol 2022; 13: 934947
- 29 Shinzato T, Sato R, Suzuki K. et al. Proposal of therapeutic curcumin derivatives for Alzheimer's disease based on ab initio molecular simulations. Chem Phys Lett 2020; 738: 136883
- 30 Guo H, Zhao CY, Zhan LB. et al. Analysis of the mechanism of treating hypertension, Type 2 diabetes, and Alzheimer's disease with Liuwei Dihuang pill based on network pharmacology. Pharmacol Clin Chin Mater Med 2021; 37 (01) 41-49
- 31 Zhao C, Jiang Z, Tian L, Tang L, Zhou A, Dong T. Bioinformatics-based approach for exploring the immune cell infiltration patterns in Alzheimer's disease and determining the intervention mechanism of Liuwei Dihuang pill. Dose Response 2022 ;20(3):15593258221115563
- 32 Li Q, Jia C, Wu H. et al. Nao Tan Qing ameliorates Alzheimer's disease-like pathology by regulating glycolipid metabolism and neuroinflammation: a network pharmacology analysis and biological validation. Pharmacol Res 2022; 185: 106489
- 33 Shen ZJ, Fu YB, Hou JL. et al. Integrating network pharmacology, UPLC-Q-TOF-MS and molecular docking to investigate the effect and mechanism of Chuanxiong Renshen decoction against Alzheimer's disease. Chin Med 2022; 17 (01) 143
- 34 Yang WT, Zheng XW, Chen S. et al. Chinese herbal medicine for Alzheimer's disease: clinical evidence and possible mechanism of neurogenesis. Biochem Pharmacol 2017; 141: 143-155
- 35 Wang XC, Chu CL, Lu K, Chen X, Jin XQ, Quan SJ. The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: a network meta-analysis. Medicine (Baltimore) 2022; 101 (46) e31243
- 36 Gross T, Mapstone M, Miramontes R. et al. Toward reproducible results from targeted metabolomic studies: perspectives for data pre-processing and a basis for analytic pipeline development. Curr Top Med Chem 2018; 18 (11) 883-895